Gallstone disease shown to be strong predictor of pancreatic cancer
Patients with pancreatic ductal adenocarcinoma (PDAC) were six times more likely to have had gallstone disease within the year prior to diagnosis than non-cancer patients, suggesting gallstones could be a warning sign for this aggressive and deadly cancer, according to research to be presented at Digestive Disease Week (DDW) 2022.
PDAC is the most common pancreatic cancer, accounting for more than 90% of cases, and it is often fatal because it tends to be diagnosed in late stages.
“Pancreatic cancer can be difficult to diagnose and then chances of survival are slim. Our findings suggest that gallstone disease may be a way to better diagnose this type of cancer – meaning we could save more lives,” said Marianna Papageorge, MD, lead researcher on the study and research fellow at Boston Medical Center.
Using records in the SEER-Medicare database from 2008 to 2015, researchers identified 18,700 PDAC patients and compared them to an average of 99,287 patients per year from the same database. In the year before diagnosis, 4.7 percent of the PDAC patients had a diagnosis of gallstone disease and 1.6 percent had their gallbladders removed. Among the non-cancer patients, only 0.8 percent had gallstones and only 0.3 percent had their gallbladders removal.
“Gallstone disease does not cause pancreatic cancer but understanding its association with PDAC can help combat the high mortality rate with pancreatic cancer by providing the opportunity for earlier diagnosis and treatment,” Dr. Papageorge said.
Since many people have gallstones but do not develop pancreatic cancer, future research could look more closely at laboratory findings and imaging to see if there are specific factors related to gallbladder disease that could further distinguish which patients might have or develop pancreatic cancer, Papageorge commented.
“It is such a terrible disease, and survival is so low,” Dr. Papageorge continued. “People present at such advanced stages, so anything we can do to try to diagnose people earlier and make sure that they're getting curative treatment is crucial. This might be a key to better understanding next steps in screening, management and earlier diagnosis.”
DDW Presentation Details
Dr. Papageorge will present data from the study, “Gallstone disease in the year prior to pancreatic cancer diagnosis: An opportunity for action,” abstract 761, on Monday, May 23, at 4:12 p.m. PDT.
Digestive Disease Week takes place May 21-24 in San Diego, California and virtually. The meeting showcases more than 3,100 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at www.ddw.org.
Other News
Featured Supplier
With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions aiming to improve clinical results and optimise workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating theatres, sterile reprocessing and life science.
Upcoming Events
BSG LIVE 22
ICC, Birmingham
20th – 23rd June 2022
EBME Expo 2022
Coventry Building Society Arena, Phoenix Way, Rowleys Green, Coventry CV6 6GE
28th - 29th June
Infection 360: What's trending in infection prevention & control
Edgbaston Stadium, Birmingham
27-28 September 2022
IP2022 IS COMING TO BOURNEMOUTH IN OCTOBER 2022
Bournemouth
17-19 October 2022
UKHCA Conference: Listen Up
Pendulum Hotel and Manchester Conference Centre, Manchester
3rd November 2022
MEDICA 2022
Dusseldorf Germany
14th November - 17th November
Access the latest issue of Clinical Services Journal on your mobile device together with an archive of back issues.
Download the FREE Clinical Services Journal app from your device's App store